{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:54:35Z","timestamp":1790610875921,"version":"4.1.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Beta-amyloid (Abeta) and tau protein in cerebrospinal fluid (CSF) are established diagnostic biomarkers for Alzheimer\u2019s disease (AD). However, these biomarkers may not the only ones existing parameters that reflect Alzheimer\u2019s disease neuropathological change. The use of quantitative metabolomics approach could provide novel insights into dementia progression and identify key metabolic alterations in CSF and serum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the present study, we quantified a set of 45 metabolites in CSF (71 patients) and 27 in serum (76 patients) in patients with mild cognitive impairment (MCI), AD, and controls using nuclear magnetic resonance (NMR)-based metabolomics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found significantly reduced CSF (1.32-fold,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0195) and serum (1.47-fold,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0484) levels of the ketone body acetoacetate in AD and MCI patients. Additionally, we found decreased levels (1.20-fold,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0438) of the branched-chain amino acid (BCAA) valine in the CSF of AD patients with increased valine degradation pathway metabolites (such as 3-hydroxyisobutyrate and \u03b1-ketoisovalerate). Moreover, we discovered that CSF 2-hydroxybutyrate is dramatically reduced in the MCI patient group (1.23-fold,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.039). On the other hand, vitamin C (ascorbate) was significantly raised in CSF of these patients (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.008). We also identified altered CSF protein content, 1,5-anhydrosorbitol and fructose as further metabolic shifts distinguishing AD from MCI. Significantly decreased serum levels of the amino acid ornithine were seen in the AD dementia group when compared to healthy controls (1.36-fold,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.011). When investigating the effect of sex, we found for AD males the sign of decreased 2-hydroxybutyrate and acetoacetate in CSF while for AD females increased serum creatinine was identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Quantitative NMR metabolomics of CSF and serum was able to efficiently identify metabolic changes associated with dementia groups of MCI and AD patients. Further, we showed strong correlations between these changes and well-established metabolomic and clinical indicators like Abeta.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2023.1219718","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T06:42:05Z","timestamp":1692859325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Metabolomic profiling of CSF and blood serum elucidates general and sex-specific patterns for mild cognitive impairment and Alzheimer\u2019s disease patients"],"prefix":"10.3389","volume":"15","author":[{"given":"Georgy","family":"Berezhnoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Laske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1471-4159.2004.02864.x","article-title":"Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer\u2019s disease and link to cognitive impairment.","volume":"92","author":"Ahmed","year":"2005","journal-title":"J. Neurochem"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/metabo10060251","article-title":"Pursuing experimental reproducibility: An efficient protocol for the preparation of cerebrospinal fluid samples for NMR-based metabolomics and analysis of sample degradation.","volume":"10","author":"Albrecht","year":"2020","journal-title":"Metabolites"},{"key":"B3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3233\/JPD-171127","article-title":"Correlations between methionine cycle metabolism, COMT genotype, and polyneuropathy in L-Dopa treated Parkinson\u2019s disease: A preliminary cross-sectional study.","volume":"7","author":"Andr\u00e9asson","year":"2017","journal-title":"J. Parkinsons Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/CON.0000000000000307","article-title":"Alzheimer disease.","volume":"22","author":"Apostolova","year":"2016","journal-title":"Continuum"},{"key":"B5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.arr.2016.09.005","article-title":"Sex differences in the prevalence and incidence of mild cognitive impairment: A meta-analysis.","volume":"35","author":"Au","year":"2017","journal-title":"Ageing Res. Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103517","article-title":"Transcriptomics in Alzheimer\u2019s disease: Aspects and challenges.","volume":"21","author":"Bagyinszky","year":"2020","journal-title":"Int. J. Mol. Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012472","article-title":"Quantitative NMR-based lipoprotein analysis identifies elevated HDL-4 and triglycerides in the serum of Alzheimer\u2019s disease patients.","volume":"23","author":"Berezhnoy","year":"2022","journal-title":"Int. J. Mol. Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2021.111264","article-title":"Plasma phosphatidylcholines and vitamin B12\/folate levels are possible prognostic biomarkers for progression of Alzheimer\u2019s disease.","volume":"147","author":"Blasko","year":"2021","journal-title":"Exp. Gerontol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00814-7","article-title":"An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer\u2019s disease.","volume":"13","author":"Clark","year":"2021","journal-title":"Alzheimers Res. Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1056\/NEJMoa1215740","article-title":"Glucose levels and risk of dementia.","volume":"369","author":"Crane","year":"2013","journal-title":"N. Engl. J. Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/nyas.12999","article-title":"Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer\u2019s disease: Brain glucose and ketone uptake in Alzheimer\u2019s disease.","volume":"1367","author":"Cunnane","year":"2016","journal-title":"Ann. N.Y. Acad. Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0270-x","article-title":"One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: Homocysteine and beyond.","volume":"9","author":"Dayon","year":"2017","journal-title":"Alzheimer Res. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000469669","article-title":"Serum creatinine: Not so simple!","volume":"136","author":"Delanaye","year":"2017","journal-title":"Nephron"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1021\/ac051632c","article-title":"Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1 H NMR metabonomics.","volume":"78","author":"Dieterle","year":"2006","journal-title":"Anal. Chem"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9887","DOI":"10.1021\/ac5025039","article-title":"Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping.","volume":"86","author":"Dona","year":"2014","journal-title":"Anal. Chem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bioorg.2006.07.005","article-title":"Non-enzymatic interactions of glyoxylate with lysine, arginine, and glucosamine: A study of advanced non-enzymatic glycation like compounds.","volume":"35","author":"Dutta","year":"2007","journal-title":"Bioorgan. Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/brain\/awab405","article-title":"Amyloid pathology but not APOE \u03b54 status is permissive for tau-related hippocampal dysfunction.","volume":"145","author":"D\u00fczel","year":"2022","journal-title":"Brain"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74823-1","article-title":"Predicting human health from biofluid-based metabolomics using machine learning.","volume":"10","author":"Evans","year":"2020","journal-title":"Sci. Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007045","article-title":"NMR metabolomics of cerebrospinal fluid differentiates inflammatory diseases of the central nervous system.","volume":"12","author":"French","year":"2018","journal-title":"PLoS Negl. Trop. Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010883","article-title":"\u03b1-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population.","volume":"5","author":"Gall","year":"2010","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119452","article-title":"Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer\u2019s disease.","volume":"10","author":"Graham","year":"2015","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0212-x","article-title":"Hexokinases link DJ-1 to the PINK1\/parkin pathway.","volume":"12","author":"Hauser","year":"2017","journal-title":"Mol. Neurodegen."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jnc.13107","article-title":"Effects of ketone bodies in Alzheimer\u2019s disease in relation to neural hypometabolism, \u03b2-amyloid toxicity, and astrocyte function.","volume":"134","author":"Hertz","year":"2015","journal-title":"J. Neurochem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz9360","article-title":"Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease.","volume":"6","author":"Higginbotham","year":"2020","journal-title":"Sci Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.1040476","article-title":"Decreased circulating branched-chain amino acids are associated with development of Alzheimer\u2019s disease in elderly individuals with mild cognitive impairment.","volume":"9","author":"Ikeuchi","year":"2022","journal-title":"Front. Nutr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3233\/JAD-191226","article-title":"Metabolic profiles help discriminate mild cognitive impairment from dementia stage in Alzheimer\u2019s disease.","volume":"74","author":"J\u00e4\u00e4skel\u00e4inen","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11306-008-0106-6","article-title":"Quantification of 1H NMR spectra of human cerebrospinal fluid: A protocol based on constrained total-line-shape analysis.","volume":"4","author":"Jukarainen","year":"2008","journal-title":"Metabolomics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181758","article-title":"Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance.","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/bmj.322.7300.1447","article-title":"Midlife vascular risk factors and Alzheimer\u2019s disease in later life: Longitudinal, population based study.","volume":"322","author":"Kivipelto","year":"2001","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3109\/1354750X.2011.635806","article-title":"A biomarker for severity of Alzheimer\u2019s disease: 1 H-NMR resonances in cerebrospinal fluid correlate with performance in mini-mental-state-exam.","volume":"17","author":"Kork","year":"2012","journal-title":"Biomarkers"},{"key":"B31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/NEN.0000000000000181","article-title":"Expression of regulatory proteins in choroid plexus changes in early stages of Alzheimer disease.","volume":"74","author":"Krzyzanowska","year":"2015","journal-title":"J. Neuropathol. Exp. Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.113080","article-title":"Circulatory Glutamine\/Glucose ratio for evaluating disease activity in Takayasu arteritis: A NMR based serum metabolomics study.","volume":"180","author":"Kumar","year":"2020","journal-title":"J. Pharm. Biomed. Anal"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/jnnp-2015-311171","article-title":"Diagnosis of dementias by high-field 1H MRS of cerebrospinal fluid.","volume":"86","author":"Laakso","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12931-1","article-title":"Branched-chain amino acids and Alzheimer\u2019s disease: A Mendelian randomization analysis.","volume":"7","author":"Larsson","year":"2017","journal-title":"Sci. Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/s43440-020-00107-0","article-title":"Clinical significance of fluid biomarkers in Alzheimer\u2019s Disease.","volume":"72","author":"Lewczuk","year":"2020","journal-title":"Pharmacol. Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/alz.12353","article-title":"Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer\u2019s disease.","volume":"17","author":"Libiger","year":"2021","journal-title":"Alzheimers Dement."},{"key":"B37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0378-4347(84)80031-6","article-title":"Hydroxycarboxylic and oxocarboxylic acids in urine: Products from branched-chain amino acid degradation and from ketogenesis.","volume":"309","author":"Liebich","year":"1984","journal-title":"J. Chromatogr. B Biomed. Sci. Applic."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-8-38","article-title":"Blood\u2013brain-barriers in aging and in Alzheimer\u2019s disease.","volume":"8","author":"Marques","year":"2013","journal-title":"Mol. Neurodegen"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1064","article-title":"Biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.","volume":"302","author":"Mattsson","year":"2009","journal-title":"JAMA"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2012.00025","article-title":"Modulation of iron metabolism in aging and in Alzheimer\u2019s disease: Relevance of the choroid plexus.","volume":"6","author":"Mesquita","year":"2012","journal-title":"Front. Cell Neurosci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1515\/cclm-2012-0829","article-title":"Pentosidine determination in CSF: A potential biomarker of Alzheimer\u2019s disease?","volume":"52","author":"Monacelli","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/acn3.530","article-title":"Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer\u2019s brain.","volume":"5","author":"Mullins","year":"2018","journal-title":"Ann. Clin. Transl. Neurol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0119-x","article-title":"Comparative analysis of cerebrospinal fluid metabolites in Alzheimer\u2019s disease and idiopathic normal pressure hydrocephalus in a Japanese cohort.","volume":"6","author":"Nagata","year":"2018","journal-title":"Biomark. Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jns.2017.04.033","article-title":"Effects of age and glucose levels on lactate levels in cerebrospinal fluid examination of neurodegenerative diseases.","volume":"378","author":"Nakano","year":"2017","journal-title":"J. Neurol. Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00726-021-02943-7","article-title":"High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer\u2019s disease.","volume":"53","author":"Nuzzo","year":"2021","journal-title":"Amino Acids"},{"key":"B46","doi-asserted-by":"publisher","first-page":"W388","DOI":"10.1093\/nar\/gkab382","article-title":"MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights.","volume":"49","author":"Pang","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/474296","article-title":"Ketogenic diet in neuromuscular and neurodegenerative diseases.","volume":"2014","author":"Paoli","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jnc.15183","article-title":"Plasma isoprostanoids assessment as Alzheimer\u2019s disease progression biomarkers.","volume":"157","author":"Pe\u00f1a-Bautista","year":"2021","journal-title":"J. Neurochem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1089\/ars.2019.7763","article-title":"Central and peripheral metabolic defects contribute to the pathogenesis of Alzheimer\u2019s disease: Targeting mitochondria for diagnosis and prevention.","volume":"32","author":"Peng","year":"2020","journal-title":"Antioxid. Redox Signal."},{"key":"B50","first-page":"161","article-title":"Clinical pharmacology of the dietary supplement creatine monohydrate.","volume":"53","author":"Persky","year":"2001","journal-title":"Pharmacol. Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11010-019-03553-4","article-title":"AGE\u2013RAGE stress: A changing landscape in pathology and treatment of Alzheimer\u2019s disease.","volume":"459","author":"Prasad","year":"2019","journal-title":"Mol. Cell Biochem"},{"key":"B52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jalz.2016.08.003","article-title":"Association of blood lipids with Alzheimer\u2019s disease: A comprehensive lipidomics analysis.","volume":"13","author":"Proitsi","year":"2017","journal-title":"Alzheimers Dement"},{"key":"B53","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000022031","article-title":"Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients.","volume":"44","author":"Redjems-Bennani","year":"1998","journal-title":"Gerontology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00702-004-0128-9","article-title":"CSF-methionine is elevated in psychotic patients.","volume":"111","author":"Regland","year":"2004","journal-title":"J. Neural Transm"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183228","article-title":"Metabolite patterns predicting sex and age in participants of the Karlsruhe Metabolomics and Nutrition (KarMeN) study.","volume":"12","author":"Rist","year":"2017","journal-title":"PLoS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12121277","article-title":"Quantitative serum NMR spectroscopy stratifies COVID-19 patients and sheds light on interfaces of host metabolism and the immune response with cytokines and clinical parameters.","volume":"12","author":"R\u00f6ssler","year":"2022","journal-title":"Metabolites"},{"key":"B57","first-page":"614","article-title":"Serum metabolomic profiles suggest influence of sex and oral contraceptive use.","volume":"6","author":"Ruoppolo","year":"2014","journal-title":"Am. J. Transl. Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease.","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0197-4580(00)00253-0","article-title":"Increased protein glycation in cerebrospinal fluid of Alzheimer\u2019s disease.","volume":"22","author":"Shuvaev","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213523","article-title":"Branched-chain amino acids are linked with Alzheimer\u2019s disease-related pathology and cognitive deficits.","volume":"11","author":"Siddik","year":"2022","journal-title":"Cells"},{"key":"B61","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/nbm.1428","article-title":"NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases - a diagnostic tool?","volume":"23","author":"Sinclair","year":"2009","journal-title":"NMR Biomed"},{"key":"B62","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(76)90541-9","article-title":"Insulin, glucagon, aminoacid imbalance, and hepatic encephalopathy.","volume":"308","author":"Soeters","year":"1976","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022857118","article-title":"Whole-blood metabolomics of dementia patients reveal classes of disease-linked metabolites.","volume":"118","author":"Teruya","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"B64","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.trci.2018.10.005","article-title":"Dietary intake of branched-chain amino acids in a mouse model of Alzheimer\u2019s disease: Effects on survival, behavior, and neuropathology.","volume":"4","author":"Tournissac","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063644","article-title":"Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer\u2019s disease using metabolomics.","volume":"8","author":"Trushina","year":"2013","journal-title":"PLoS One"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032737","article-title":"Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer\u2019s disease.","volume":"7","author":"Trushina","year":"2012","journal-title":"PLoS One"},{"key":"B67","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jalz.2018.01.003","article-title":"Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer\u2019s disease: A prospective study in eight cohorts.","volume":"14","author":"Tynkkynen","year":"2018","journal-title":"Alzheimers Dement"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0551-7","article-title":"Systemic and central nervous system metabolic alterations in Alzheimer\u2019s disease.","volume":"11","author":"van der Velpen","year":"2019","journal-title":"Alzheimers Res. Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1021\/acs.jproteome.9b00850","article-title":"Fingerprinting Alzheimer\u2019s disease by 1 H nuclear magnetic resonance spectroscopy of cerebrospinal fluid.","volume":"19","author":"Vignoli","year":"2020","journal-title":"J. Prot. Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10545-010-9236-x","article-title":"Enzymology of the branched-chain amino acid oxidation disorders: The valine pathway.","volume":"35","author":"Wanders","year":"2012","journal-title":"J. Inherit Metab. Dis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1021\/pr5000895","article-title":"Plasma metabolite profiles of Alzheimer\u2019s disease and mild cognitive impairment.","volume":"13","author":"Wang","year":"2014","journal-title":"J. Prot. Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01223","article-title":"The differences of serum metabolites between patients with early-stage Alzheimer\u2019s disease and mild cognitive impairment.","volume":"10","author":"Weng","year":"2019","journal-title":"Front. Neurol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.mehy.2005.01.016","article-title":"Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer\u2019s disease.","volume":"64","author":"Yamagishi","year":"2005","journal-title":"Med. Hypoth"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-2-34","article-title":"A low-carbohydrate, ketogenic diet to treat type 2 diabetes.","volume":"2","author":"Yancy","year":"2005","journal-title":"Nutr. Metab."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00585","article-title":"Ketone bodies in neurological diseases: Focus on neuroprotection and underlying mechanisms.","volume":"10","author":"Yang","year":"2019","journal-title":"Front. Neurol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3233\/JAD-200305","article-title":"A community-based study identifying metabolic biomarkers of mild cognitive impairment and Alzheimer\u2019s disease using artificial intelligence and machine learning.","volume":"78","author":"Yilmaz","year":"2020","journal-title":"J. Alzheimer Dis"},{"key":"B77","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/jnr.24064","article-title":"The vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correction","volume":"95","author":"Zilberter","year":"2017","journal-title":"J. Neurosci. Res"}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1219718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T06:42:10Z","timestamp":1692859330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1219718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":77,"alternative-id":["10.3389\/fnagi.2023.1219718"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2023.1219718","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"article-number":"1219718"}}